- Home
- MRM vs CLRB Comparison
MRM vs CLRB Comparison
Compare MRM & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- CLRB
- Stock Information
- Founded
- MRM 2000
- CLRB 2002
- Country
- MRM Japan
- CLRB United States
- Employees
- MRM N/A
- CLRB N/A
- Industry
- MRM Other Consumer Services
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- CLRB Health Care
- Exchange
- MRM Nasdaq
- CLRB Nasdaq
- Market Cap
- MRM 12.2M
- CLRB 10.7M
- IPO Year
- MRM 2020
- CLRB N/A
- Fundamental
- Price
- MRM $0.99
- CLRB $0.24
- Analyst Decision
- MRM
- CLRB Buy
- Analyst Count
- MRM 0
- CLRB 2
- Target Price
- MRM N/A
- CLRB $28.00
- AVG Volume (30 Days)
- MRM 95.4K
- CLRB 3.3M
- Earning Date
- MRM 01-01-0001
- CLRB 11-18-2024
- Dividend Yield
- MRM N/A
- CLRB N/A
- EPS Growth
- MRM N/A
- CLRB N/A
- EPS
- MRM N/A
- CLRB N/A
- Revenue
- MRM $44,462,062.00
- CLRB N/A
- Revenue This Year
- MRM N/A
- CLRB N/A
- Revenue Next Year
- MRM N/A
- CLRB N/A
- P/E Ratio
- MRM N/A
- CLRB N/A
- Revenue Growth
- MRM 2.80
- CLRB N/A
- 52 Week Low
- MRM $0.90
- CLRB $0.22
- 52 Week High
- MRM $8.39
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- MRM 33.16
- CLRB 18.75
- Support Level
- MRM $0.93
- CLRB $0.27
- Resistance Level
- MRM $1.05
- CLRB $0.33
- Average True Range (ATR)
- MRM 0.08
- CLRB 0.03
- MACD
- MRM 0.06
- CLRB 0.05
- Stochastic Oscillator
- MRM 25.53
- CLRB 10.38
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.